Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who can’t get the blockbuster drug through insurance.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Dr. Mehmet Oz, the former surgeon and television host, was nominated to head the Centers for Medicare and Medicaid Services.

Dawn Maroney became president of Alignment Health in January at a critical time for the health insurance industry.

Spring has nearly sprung and round two of the Inflation Reduction Act (IRA)’s negotiation period has begun. | All of the ...

A new study suggests blockbuster weight loss drugs Wegovy and Zepbound are not cost-effective at their current prices, despite the proven health benefits. The study, published in JAMA Health Forum and ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

In January, CMS selected Ozempic, Rybelsus, Wegovy, Trelegy Ellipta ... round of negotiations aimed at reducing drug costs for Medicare beneficiaries. On March 14, CMS said it had signed ...

They’re expensive and aren’t a short-term fix, but Ozempic and Wegovy show great promise in regulating weight. | Opinion ...

Eli Lilly on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 ...